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Abstract
Background:  In breast cancer current guidelines do not recommend the routine use of serum tumour markers.
Differently, we observed that CEA-TPA-CA15.3 (carcinoembryonic (CEA) tissue polypeptide (TPA) and cancer associated
115D8/DF3 (CA15.3) antigens) panel permits early detection and treatment for most relapsing patients. As high sensitivity
and specificity and different cut-off values have been reported for mucin-like carcinoma associated antigen (MCA), we
compared MCA with the above mentioned tumour markers and MCA-CA15.3 with the CEA-TPA-CA15.3 panel.
Methods: In 289 breast cancer patients submitted to an intensive post-operative follow-up with tumour markers, we
compared MCA (cut-off values, ≥ 11 and ≥ 15 U/mL) with CEA or CA15.3 or TPA for detection of relapse. In addition, we
compared the MCA-CA15.3 and CEA-TPA-CA15.3 tumour marker panels.
Results: Distant metastases occurred 19 times in 18 (6.7%) of the 268 patients who were disease-free at the beginning of
the study. MCA sensitivity with both cut-off values was higher than that of CEA or TPA or CA15.3 (68% vs 10%, 26%, 32%
and 53% vs 16%, 42%, 32% respectively). With cut-off ≥ 11 U/mL, MCA showed the lowest specificity (42%); with cut-off
≥ 15 U/mL, MCA specificity was similar to TPA (73% vs 72%) and lower than that of CEA and CA15.3 (96% and 97%
respectively). With ≥ 15 U/mL MCA cut-off, MCA sensitivity increased from 53% to 58% after its association with CA15.3.
Sensitivity of CEA-TPA-CA15.3 panel was 74% (14 of 19 recurrences). Eight of the 14 recurrences early detected with
CEA-TPA-CA15.3 presented as a single lesion (oligometastatic disease) (5) or were confined to bony skeleton (3) (26% and
16% respectively of the 19 relapses). With ≥ 11 U/mL MCA cut-off, MCA-CA15.3 association showed higher sensitivity but
lower specificity, accuracy and positive predictive value than the CEA-TPA-CA15.3 panel.
Conclusion: At both the evaluated cut-off values serum MCA sensitivity is higher than that of CEA, TPA or CA15.3 but
its specificity is similar to or lower than that of TPA. Overall, CEA-TPA-CA15.3 panel is more accurate than MCA-CA15.3
association and can "early" detect a few relapsed patients with limited metastatic disease and more favourable prognosis.
These findings further support the need for prospective randomised clinical trial to assess whether an intensive post-
operative follow-up with an appropriate use of serum tumour markers can significantly improve clinical outcome of early
detected relapsing patients.
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Background
In breast cancer patients, current guidelines post-opera-
tively recommend mammography at regular intervals and
not routine use of any instrumental or laboratory test for
early detection of relapse and monitoring of metastatic
disease. In fact, in randomised trials and meta-analysis
intensive post-operative follow-up has been shown to be
useful only in early diagnosis but not in improving clini-
cal outcome and/or quality of life [1-4]. Nevertheless, in
these trials clinical-instrumental was compared with clin-
ical only follow-up and neither any serum tumour marker
panel nor appropriate criteria for its use were adopted.
Different studies appropriately using serum tumour mark-
ers within an intensive post-operative follow-up showed
that in many relapsing patients clinical-instrumental diag-
nosis was anticipated and that this anticipation permitted
an earlier treatment which significantly prolonged dis-
ease-free survival (DFS) and/or overall survival (OS) [5-
8]. Moreover we showed that this type of follow-up
strongly reduced need for conventional radiological
examinations [9-11]. Therefore, unlike current guidelines,
it is routine practice in our center to carry out an intensive
post-operative follow-up of breast cancer patients using
both serum tumour markers and imaging techniques.
Carcinoembryonic (CEA) and breast cancer associated
115D8/DF3 (CA15.3) antigens are the serum tumour
markers commonly used for post-operative monitoring of
breast cancer [1] although many other tumour markers
have been investigated [12-17]. We reported similar sensi-
tivity for TPA and CA15.3, which, however, is higher than
that of CEA. TPA showed much lower specificity than
CA15.3 and CEA. The association of these three markers
increased sensitivity with a slight decrease of specificity [4-
6,18].
CA15.3 is one of the mucin-like biomarkers which also
recently have been reported among the most useful mark-
ers to detect and monitor metastatic breast cancer [8,19].
The mucin-like carcinoma associated antigen (MCA) is
another widely used test to assay MUC-1. When it has
been used alone, high sensitivity and specificity have been
reported [17,20,21]. This suggests the association with
CA15.3. However, different cut-off values have been
reported for MCA [17,20]. Besides conflicting data have
been found both as to MCA sensitivity and specificity
compared to CA15.3 [22-25] and the MCA-CA15.3 use-
fulness [14,15,22,26,27]. Finally, as far as we know, no
previous study compared MCA-CA15.3 to CEA-TPA-
CA15.3 association. Therefore, in this study we compared
sensitivity and specificity of MCA (with two commonly
used cut-off values: ≥ 11 and ≥ 15 UI/mL) with that of
CEA, CA15.3, TPA for early detection of relapse. Moreo-
ver, also we compared the diagnostic accuracy and predic-
tive value of the MCA-CA15.3 association to that of CEA-
TPA-CA15.3 panel.
Methods
Patients' follow-up
From March 2000 to September 2003, 289 breast cancer
patients aged 27 to 80 years (median 51) were submitted
to an intensive post-operative follow-up with serial serum
determination of CEA, CA15.3, TPA and MCA. At entry
268 patients (93%) were disease-free (M0) and 21 (7%)
showed distant metastases (M1). At the post-operative
histology 83 (31%) of the 268 disease-free patients were
N+ while the 185 remaining were N-. Premenopausals
were 162 (56%) of all the 289 studied patients. Soon after
primary surgery, all estrogen (ER) and/or progesterone
receptor(PgR) positive patients received hormone ther-
apy. Moreover, all N+ and 129 N- disease-free patients,
consistent with the current international guidelines,
received adjuvant chemotherapy. As to the interval time of
post-operative monitoring, patients were divided into 2
groups: at low and at intermediate-high risk of recurrence
according to whether they were N-PgR+ or N+ and/or PgR-
(N+ PgR+, N+ PgR-, N- PgR-) respectively. Axillary lymph-
nodes (N+/N-) [28] and progesterone (PgR+/PgR-) status
[29,30] were used to divide patients into two different risk
groups as they are commonly reported among the princi-
pal prognostic factors for relapse. The 126 low risk
patients underwent control visits every 6 months and the
remaining 142 with intermediate-high risk of recurrence
every 4 months. Post-operative follow-up was 16 ± 8
months (m ± sd ; range 6–37 months). At each control
visit, history, routine lab and serum CEA, CA15.3, TPA
and MCA measurement were carried out.
Baseline Sx-ray was performed to identify benign lesions
due to inflammatory and/or degenerative disease. As to
other conventional instrumental examinations, bone
scintigraphy (BS) and liver echography (LE) have been
reported to be more accurate than chest x-ray (CXR) to
"early" detect recurrences [7,9,10,16,31,32]. Therefore, BS
and LE were serially performed every 24–30 months and
CXR at more prolonged intervals (mean value 42
months).
The reason for serial BS, LE and CXR examinations, even
if more prolonged, was to detect asymptomatic relapses
falsely negative with serum tumour markers, which as we
have previously reported [4,7,9-11] are about 15–25%
using CEA-TPA-CA15.3 tumour marker panel.
Patients suspected of relapse with CEA-TPA-CA15.3
tumour marker panel immediately underwent the stand-
ard radiological examinations (BS, LE and CXR). If these
examinations were pathological or equivocal, patients
immediately were selected to be further investigated asBMC Cancer 2006, 6:269 http://www.biomedcentral.com/1471-2407/6/269
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follows. All hot spots on the bone scintigraphy with an
equivocal interpretation were examined by computed
tomography and/or magnetic resonance imaging (MRI).
The lesions that were considered equivocal by conven-
tional chest x-ray were clarified by computed tomography
or bronchoscopy and cytologic study. The lesions felt to
be equivocal at liver echography were clarified by com-
puted tomography or fine needle aspiration cytology
guided by liver echography when possible. The patients
with equivocal standard radiological examinations and
concomitantly not suspected of relapse with the CEA-TPA-
CA15.3 tumour marker panel, were regularly followed-up
as above described.
All patients gave their consent to be post-operatively mon-
itored with all instrumental and laboratory examinations
described in the paper.
Tumour markers
Serum CEA, TPA, CA15.3 and MCA concentrations were
measured in fasting patients by commercial immunoenz-
imatic assays: Abbott, Rome (Italy) for CEA and CA15.3;
DRG, Marburg (Germany) for TPA; Roche Diagnostics,
Manheim (Germany) for MCA. The within and between
assay coefficients of variation for CEA, CA15.3, TPA and
MCA were all less than 5% and 6% respectively. Serum
levels > 7 ng/mL, > 95 U/L and > 32 U/mL were consid-
ered to be elevated for CEA, TPA and CA15.3 respectively;
for MCA, ≥ 11 and ≥ 15 U/mL cut-off values were consid-
ered. We identified the causes of false positive tumour
marker increase [17]. As previously described [4,9,10], a
dynamic evaluation of tumour markers was made and in
cases of a high tumour marker value a further blood sam-
ple was drawn two weeks to a month after the previous
elevated value. If the re-measured tumour marker value
had decreased to a normal value, the initial elevated value
was considered to be an isolated elevated value (IEV). The
elevated tumour marker was considered to be progressive
(PI) when it was 30%, or more, higher in the sample
which followed the initial elevated value. Otherwise, two
equally high values were regarded to be a constant eleva-
tion (CE). Only CE and/or PI were considered a signifi-
cant tumour marker increase.
As previously reported [9-11] in our clinical practice only
patients with CE or PI in one or more tumour markers,
clearly unexplained by any other condition, are consid-
ered suspected of tumour relapse.
Tumour marker lead time was the time from the suspicion
of relapse with serum tumour marker to confirmation of
relapse by radiological examinations. When a clinically
disease-free patient was suspected of relapse by re-testing
of tumour markers at the regular control visit, 15 to 30
days were necessary to carry out the common (bone scin-
tigraphy, liver echography, chest x-ray) and in case of their
equivocal result, more accurate radiological examinations
(CT, MRI) to confirm or rule out the suspicion. Radiolog-
ical investigations performed during this 15 to 30 days
interval time and confirming the initial suspicion by
tumour markers were considered as they had been per-
formed at the same time of tumour marker re-testing;
therefore in this case tumour marker lead time was com-
puted as zero. When a patient became suspected of metas-
tases by symptoms before the routine testing of serum
tumour markers (i.e. in the interval between two regular
control visits), at this time immediately the entire planned
procedure was carried out to confirm or rule out the sus-
picion. Again, as above mentioned, the time necessary for
the entire procedure took about 15 to 30 days and this
interval time was not considered for the calculation of the
tumour marker lead time. In fact, when suspicion of
metastases was confirmed by radiological examinations
and not by tumour marker panel, tumour marker panel
was considered falsely negative. When suspicion of metas-
tases was confirmed by radiological examinations and by
tumour marker panel as well, the tumour marker panel
lead time was considered zero if symptoms suspicious of
metastases had appeared at the same time the entire pro-
cedure for confirmation was started; if symptoms suspi-
cious of metastases had previously appeared, clinical
symptoms only were considered the first signal of relapse
and tumour marker panel was considered falsely negative.
Statistical analysis
Sensitivity was defined as TP/(TP+FN)% specificity as TN/
(TN+FP)%, accuracy as TN+TP/(TN+FN+TP+FP), positive
predictive value as TP/(TP+FP), negative predictive value
as TN/(TN+FN), where FP = false positive, FN = false neg-
ative, TP = true positive, TN = true negative. Two analyses
were performed. In a first analysis only dynamic evalua-
tion of tumour markers was taken into account without
considering clinical and laboratory data. In this analysis
tumour marker assay with CE or PI in one or more mark-
ers was defined as a probably positive test. In a further
analysis dynamic evaluation of tumour markers was con-
sidered with an accurate clinical history and laboratory
examinations. In this analysis tumour marker assay with
CE or PI in one or more markers, unexplained by any con-
comitant transient or chronic benign pathology, that is for
unknown reasons, was defined as a probably positive test.
In both analyses tumour marker assay with normal or IEV
was defined as a probably negative test. In the further
analysis also CE or PI in one or more markers likely due
to a clear concomitant benign pathology was defined as a
probably negative test.
A probably positive test, according to whether it was or
was not confirmed by monitoring to death or by the
development of a definite clinical-imaging course after theBMC Cancer 2006, 6:269 http://www.biomedcentral.com/1471-2407/6/269
Page 4 of 9
(page number not for citation purposes)
initial result, was defined as true or false positive respec-
tively. A probably negative test, according to whether it
was or was not confirmed by monitoring by at least one
year without any clinical-imaging sign of relapse, was
defined as true or false negative.
Because one of 18 relapsed patients recurred twice during
the follow-up (see the Result section), statistical analysis
was performed considering 19 relapses.
Results
During the post-operative follow-up distant metastases
occurred in 18 (6.7%) of the 268 disease-free patients.
Nine (50%) of these 18 patients were postmenopausals.
One of them recurred twice. In this patient multiple bone
and liver metastases were found 9 months after she had
been rendered disease-free with surgical removal of a sin-
gle secondary liver nodule. Therefore, as total, there were
19 relapses. The organs initially involved in the relapse
were: bone (8), viscera (8), soft tissue (1), bone and vis-
cera (2). The number of the lesions was: < 3, > 3 < 10 and
> 10 in 8, 6 and 5 relapses respectively.
Sensitivity of each tumour marker: CEA,TPA,CA15.3 and
MCA (≥ 11 or ≥ 15 U/mL cut-off value) (Table 1)
MCA cut-off value ≥ 11 U/mL. MCA, CEA, CA15.3 and
TPA were the first finding in 2 to 13 relapses. In 6 relapses
for MCA and in 1 for CEA the tumour marker increase was
the only sign. In 7 relapses for MCA, in 1 for CEA and in
all 5 and 6 relapses for TPA and CA15.3 respectively the
tumour marker increase was concomitant with the
increase of other markers and/or with clinical or instru-
mental findings. The mean lead time from the tumour
marker increase to the appearance of clinical and/or
instrumental signs of the relapse ranged from 2 ± 2.8 for
CEA to 7.1 ± 6.8 months for MCA. BS alone or combined
with tumour markers (one or more) was the first finding
of relapse more frequently than LE or clinical symptoms
(4 vs 1 and 2 relapses respectively). In these instances the
mean lead time from the appearance of clinical and/or
instrumental signs to tumour marker increase ranged
from 0 for LE to 3 ± 4.2 months for clinical symptoms.
MCA cut-off value ≥ 15 U/mL. MCA, CEA, TPA and
CA15.3 were the first finding in 3 to 10 relapses. In 1
relapse for MCA and for CEA the tumour marker increase
was the only sign. In 9 relapses for MCA, in 2 for CEA and
in all 8 and 6 relapses for TPA and CA15.3 respectively the
tumour marker increase was concomitant with the
increase of other markers and/or with clinical or instru-
mental findings. The mean lead time from tumour marker
increase to the appearance of clinical and/or instrumental
signs of the relapse ranged from 2.9 ± 4 for TPA to 7.3 ±
9.4 months for CEA. Again, BS alone or combined with
tumour marker increase was the first finding of relapse
more frequently than LE or clinical symptoms (4 vs 2 and
3 relapses respectively). In these instances the mean lead
time from the appearance of clinical and/or instrumental
signs to tumour marker increase ranged from 2 ± 3.5 for
clinical symptoms to 5.5 ± 7.8 months for LE.
Table 1: Sensitivity of MCA (*≥11 or **≥15 U/mL cut-off values), CEA, TPA, CA15.3 in the early detection of 19 relapses during an 
intensive post-operative follow-up with tumour markers.
CE or PI of tumour markers as the initial pathological finding of relapse
Tumour marker type aRelapses (total, n) Sensitivity (%) Tumour marker increase Lead time (months) m + sd (range)
type n
*MCA 13 68 CE
PI
8
5
7.1 ± 6.8
(0–22)
CEA 2 10 CE
PI
0
2
2.0 ± 2.8
(0–4)
TPA 5 26 CE
PI
3
2
3.2 ± 4.4
(0–9)
CA15.3 6 32 CE
PI
5
1
4.7 ± 5.8
(0–14)
**MCA 10 53 CE
PI
7
3
6.5 ± 6.8
(0–18)
CEA 3 16 PI 3 7.3 ± 9.4
(0–18)
TPA 8 42 CE
PI
6
2
2.9 ± 4.0
(0–9)
CA15.3 6 32 CE
PI
5
1
4.7 ± 5.8
(0–14)
aTotal number of patients = 18; one patient after radical removal by surgery of a single metastatic lesion relapsed (also see Result section). 
Therefore, percentages are calculated on 19 relapses; CE = constant elevation; PI = progressive increase.BMC Cancer 2006, 6:269 http://www.biomedcentral.com/1471-2407/6/269
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Sensitivity of different tumour marker associations: MCA
(≥ 11 or ≥ 15 U/mL cut-off values) – CA15.3 and CEA-
TPA-CA15.3 panels (Table 2)
MCA cut-off value ≥ 11 U/mL. MCA-CA15.3 and CEA-
TPA-CA15.3 panels were the first finding of 13 and 10
relapses respectively. In 6 relapses for the former associa-
tion and in 2 for the latter the tumour marker increase was
the only sign while in the remaining it was the first finding
of relapse concomitant with clinical and/or instrumental
examinations. BS alone or combined with tumour marker
increase was the first finding in 4 relapses, while it
occurred in 1 relapse for LE and in 2 relapses for clinical
symptoms. In these instances the mean lead time from the
appearance of clinical and/or instrumental signs to
tumour marker increase ranged from 0 for LE to 3 ± 4.2
months for clinical symptoms.
MCA cut-off value ≥ 15 U/mL. CEA-TPA-CA15.3 panel
and MCA-CA15.3 association were the first finding of 14
and 11 relapses respectively. In 2 relapses for the former
association and in 1 relapse for the latter the tumour
marker increase was the only sign while in the remaining
it was the first finding of relapse concomitant with clinical
and/or instrumental examinations. Eight of the 14 recur-
rences "early" detected using CEA-TPA-CA15.3 tumour
marker panel presented as a single lesion (5) or confined
to bony skeleton (3). Three of the 5 recurrences that pre-
sented as single lesions involved bony skeleton and the 2
remaining liver. Therefore, "early" detected recurrences
that presented as a single lesion or limited to bony skele-
ton were 26% and 16% respectively of the 19 relapses. BS
alone or combined with tumour marker increase was the
first finding in 4 relapses, while it occurred in 2 relapses
for LE and in 3 relapses for clinical symptoms. In these
instances the mean lead time from the appearance of clin-
ical and/or instrumental signs to tumour marker increase
ranged from 1.5 ± 3 for BS to 5.5 ± 7.8 months for LE.
With both MCA cut-off values, no significant difference
occurred between the lead time of MCA-CA15.3 and CEA-
TPA-CA15.3 panels (p n.s., unpaired t test).
Specificity of each tumour marker: CEA, TPA, CA15.3,
MCA
CE and/or PI occurred in 11 patients for CEA and in 8
patients for CA15.3. Diabetes and/or hepatic steatosis (5
patients), smoking (4 patients), miscellanea (1 patient)
for CEA, chronic liver failure (2 patients), diabetes and/or
hepatic steatosis (5 patients), hepatic cyst or angioma (1
patient) for CA15.3 were the concomitant conditions
probably responsible for these two kinds of tumour
marker increase. Significant increases for unknown rea-
sons (false positives) occurred in no patient for CA15.3
and in 1 patient (0.4%) for CEA. CE and/or PI occurred in
69 patients for TPA and in 144 patients or in 68 patients
for MCA with ≥ 11 U/mL or ≥ 15 U/mL cut-off value
respectively. Chronic liver failure (7 patients), diabetes
and/or hepatic steatosis (36 patients), acute inflamma-
tion of upper airways (6 patients) for TPA, chronic liver
failure (6 patients), diabetes and/or hepatic steatosis (54
patients), acute joint inflammation (9 patients), acute
inflammation of upper airways (9 patients), hepatic cyst
and/or angioma (9 patients), miscellanea (7 patients) for
MCA with ≥ 11 U/mL cut-off value, chronic liver failure (5
patients),diabetes and/or hepatic steatosis (23 patients),
acute joint inflammation (5 patients), hepatic cyst and/or
angioma (6 patients) for MCA with ≥ 15 U/mL cut-off
value were the concomitant conditions more often prob-
ably responsible for these two different kinds of tumour
marker increase. Significant increases for unknown rea-
Table 2: Sensitivity of MCA (*≥11 or **≥15 U/mL cut-off values)-CA15.3 and CEA-TPA-CA15.3 panels in the early detection of 19 
relapses during an intensive post-operative follow-up with tumour markers.
CE or PI of tumour markers as the initial pathological finding of relapse
Tumour marker association aRelapses
(total, n)
Sensitivity
(%)
Tumour marker increase Lead time (months)
m + sd (range)
type n
*MCA-CA15.3 13 68 CE
PI
8 5 7.1 ± 6.8
(0–22)
CEA-TPA-CA15.3 10 53 CE
PI
5 5 3.9 ± 4.9
(0–14)
**MCA-CA15.3 11 58 CE
PI
8 3 5.9 ± 6.7
(0–18)
CEA-TPA-CA15.3 14 74 CE
PI
8 6 4.6 ± 5.9
(0–18)
aTotal number of patients = 18; one patient after radical removal by surgery of a single metastatic lesion relapsed (also see Result section). 
Therefore, percentages are calculated on 19 relapses; CE = constant elevation; PI = progressive increase.BMC Cancer 2006, 6:269 http://www.biomedcentral.com/1471-2407/6/269
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sons (falsely positives) were found in 10 (4%), 43
(17.2%) and 20 (8%) patients for TPA, MCA with ≥ 11 U/
mL and MCA with ≥ 15 U/mL cut-off value respectively.
Therefore, specificity was 100%, 100%, 96%, 83% and
92% for CEA, CA15.3, TPA and MCA (≥ 11 U/mL or ≥ 15
U/mL cut-off value) respectively, when an accurate history
was taken into account. Without an accurate history, spe-
cificity was 96%, 97%, 72%, 42% and 73% for CEA,
CA15.3, TPA and MCA (≥ 11 U/mL or ≥ 15 U/mL cut-off
value) respectively.
Specificity of different tumour marker associations: MCA
(≥ 11 U/mL or ≥ 15 U/mL cut-off value) – CA15.3 and
CEA-TPA-CA15.3
CE and/or PI of CEA-TPA-CA15.3 panel occurred in 77
patients. Diabetes and/or hepatic steatosis (40 patients),
chronic liver failure (7 patients), acute inflammation of
upper airways (5 patients) were the concomitant condi-
tions probably responsible for the tumour markers'
increase.
When MCA cut-off value was ≥ 11 U/mL, CE and/or PI of
MCA-CA15.3 association occurred in 151 patients. Diabe-
tes and/or hepatic steatosis (58 patients), hepatic cyst
and/or angioma (12 patients), acute joint inflammation
(10 patients), acute inflammation of upper airways (9
patients) were the concomitant conditions more often
probably responsible for these two different kinds of
tumour marker increase.
When MCA cut-off value was ≥ 15 U/mL, CE and/or PI of
MCA-CA15.3 association occurred in 72 patients. Diabe-
tes and/or hepatic steatosis (24 patients), hepatic cyst
and/or angioma (7 patients), chronic liver failure (6
patients) were the concomitant conditions more often
probably responsible for these two different kinds of
tumour marker increase. Significant increases for
unknown reasons (falsely positives) occurred in 11
(4.4%), 41 (16.4%) and 19 (7.6%) patients for CEA-TPA-
CA15.3 panel, MCA-CA15.3 association with cut-off value
≥ 11 U/mL and MCA-CA15.3 association with cut-off
value ≥ 15 U/mL respectively.
Therefore, specificity was 96%, 84% and 92% for CEA-
TPA-CA15.3 and MCA (≥ 11 U/mL or ≥ 15 U/mL cut-off
value) – CA15.3 associations respectively, when an accu-
rate history was taken into account. Without an accurate
history, specificity was 69%, 40% and 71% for CEA-TPA-
CA15.3 and MCA (≥ 11 U/mL or ≥ 15 U/mL cut-off value)
– CA15.3 associations respectively.
Reliability of MCA (≥ 11 U/mL or ≥ 15 U/mL cut-off val-
ues) – CA15.3 and CEA-TPA-CA15.3 tumour marker pan-
els with and without an accurate history (Table 3)
MCA cut-off value ≥ 11 U/mL. When dynamic evaluation
of tumour marker associations was considered with an
accurate history and laboratory examinations, specificity,
accuracy and PPV of CEA-TPA-CA15.3 tumour marker
panel were higher than the corresponding of MCA-
CA15.3 association. The opposite occurred for sensitivity
and NPV. When dynamic evaluation of tumour markers
was considered alone, specificity, accuracy, NPV and PPV
of CEA-TPA-CA15.3 tumour marker panel were higher
than the corresponding of MCA-CA15.3 association. The
opposite occurred for sensitivity.
MCA cut-off value ≥ 15 U/mL. When dynamic evaluation
of tumour marker associations was considered with an
accurate history and laboratory examinations, sensitivity,
specificity, accuracy, NPV and PPV of CEA-TPA-CA15.3
tumour marker panel were higher than the corresponding
of MCA-CA15.3 association. When dynamic evaluation of
tumour markers was considered alone, sensitivity, accu-
racy, NPV and PPV of CEA-TPA-CA15.3 tumour marker
panel were higher than the corresponding of MCA-
CA15.3 association. The opposite occurred for specificity
(Table 3).
Discussion
MCA sensitivity for "early" detection of relapses, either
with ≥ 11 or ≥ 15 UI/mL cut-off value, was higher than
that of CEA or CA15.3 or TPA. With regard to CEA, TPA
and CA15.3, CA15.3 (with MCA cut-off value ≥ 11 UI/
mL) and TPA (with MCA cut-off value ≥ 15 UI/mL) were
more sensitive than both remaining indicators. However,
only with ≥ 11 U/mL MCA cut-off value, sensitivity
increased slightly (from 53% to 58%) after the association
of MCA with CA15.3, while as we [4,7,9-11] and others
[22,26,33] previously reported, it occurred significantly
when TPA was associated with CA15.3 and CEA (Tables 1,
2). In other studies a range of MCA sensitivity similar to
CA15.3 and no significant increase in sensitivity when
MCA was combined with CA15.3 were found
[14,27,34,35]. These findings and our results suggest that,
although MCA and CA15.3 recognise distinct epitopes on
the same molecule [36], in metastatic breast cancer cells
MCA expression almost completely overlaps that of
CA15.3, while it partially occurs among CEA, TPA and
CA15.3.
Total rate of significant increases of MCA was similar to or
higher (≥ 11 or ≥ 15 UI/mL cut-off value respectively)
than that of TPA and it was higher than that of CEA and
CA15.3. Consequently, significant increases of MCA-
CA15.3 association occurred more frequently (60% vs
31%) or similarly (29% vs 31%) to those of CEA-TPA-
CA15.3 tumour marker panel. This finding does not con-
firm that MCA specificity is similar to or higher than that
of CEA and CA15.3 [17,20-23]. Moreover, our resultsBMC Cancer 2006, 6:269 http://www.biomedcentral.com/1471-2407/6/269
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show that in non relapsed patients the aspecific reasons
probably responsible for MCA increase are the same as for
TPA. The addition, at each control visit, of an accurate his-
tory and laboratory examinations to the dynamic evalua-
tion of tumour markers increased their specificity while
sensitivity remained unchanged. In fact, in 8 (42%) of the
19 relapses, a concomitant benign pathology occurred.
Nevertheless, in all of them CE and/or PI in one or more
markers could be referred to a pending relapse rather than
to the concomitant benign pathology. Conversely, among
the non relapsed patients those falsely suspected with all
evaluated tumour markers particularly MCA, TPA and
their combinations strongly decreased. In fact, CE and/or
PI, unexplained by a clear concomitant benign pathology,
ranged from 0% for CA15.3 to 17% for MCA with ≥ 11
cut-off value. When MCA cut-off value was ≥ 11 UI/mL,
MCA-CA15.3 association showed higher sensitivity and
NPV but lower specificity, accuracy and PPV than CEA-
TPA-CA15.3 panel. When MCA cut-off value was ≥ 15 UI/
mL, sensitivity, specificity, accuracy, NPV and PPV of CEA-
TPA-CA15.3 panel were higher than those of MCA-
CA15.3 association (Table 3).
Being confined to bony skeleton is considered a favoura-
ble prognostic factor for metastatic disease [37,38]. Also it
has been shown that a single lesion, i.e. minimal meta-
static disease called "stage IV oligometastatic disease",
amenable to local therapy (surgery and/or radiation) fol-
lowed by high dose chemotherapy is considered another
different favourable condition [39,40]. In these metastatic
patients with oligometastatic disease or disease limited to
bony skeleton, median overall survival 2–3 times longer
than in general metastatic population is expected. In a
general metastatic population at the presentation bony
skeleton as dominant site and oligometastatic disease
have been reported to involve about 15% [41-43] and 5–
10% [38,44,45] of patients respectively. Therefore, in this
study a post-operative follow-up with an appropriate use
of CEA-TPA-CA15.3 tumour marker panel also "early"
detected a relatively high percentage of relapsed patients
with limited metastatic disease and more favourable prog-
nosis.
Conclusion
In conclusion, data from this study point out that at both
the evaluated cut-off values serum MCA sensitivity is
higher than that of CEA, TPA and CA15.3. However, MCA
specificity is the lowest or similar to that of TPA and they
are both much lower than those of CEA and CA15.3.
Despite a higher sensitivity, this low specificity represents
an important limitation for a meaningful clinical applica-
bility of MCA and TPA as single marker. Furthermore they
suggest that overall CEA-TPA-CA15.3 panel is more suita-
ble than MCA-CA15.3 association for an intensive post-
operative follow-up of breast cancer patients with tumour
markers and that an intensive post-operative follow-up
with CEA-TPA-CA15.3 panel can early detect relapsing
patients with more favourable prognosis. These findings
further urge the need for randomised clinical trial to assess
whether an "early signalling" and treatment of distant
metastases with an appropriate use of serum tumour
markers also can significantly improve OS. Moreover, a
detailed cost-efficacy ratio analysis from these trials will
permit to draw definite conclusions about the usefulness
of serum tumour markers for a routine use.
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Tumour marker panel
Reliability CEA-TPA-CA15.3 *MCA-CA15.3 CEA-TPA-CA15.3 **MCA-CA15.3
Sensitivity % 53 (53) 68 (68) 74 (74) 58 (58)
Specificity % 96 (69) 84 (40) 96 (69) 92 (71)
Accuracy % 92.5 (68) 82.5 (42) 94 (69.5) 90 (41)
NPV % 96 (95) 97 (94) 98 (97) 97 (92)
PPV% 48 (11) 24 (8) 56 (15) 37 (7)
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PgR: progesterone receptor
Sx-ray: skeletal x-ray
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FP: false positive
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TP: true positive
TN: true negative.
NPV: negative predictive value
PPV: positive predictive value
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